Skip to main content
OpenTrials
Completed

NCT Number: NCT01241695

Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients

The purpose of the study is to determine the safety, acceptability and the efficacy of a 12-week intervention with a diabetes-specific oral nutritional supplement on glycaemic control in type 2 diabetic patients with or at risk of malnutrition

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical Practice

Stockach, Baden-Wurttemberg, 78333, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of type 2 diabetes according to the WHO diagnostic criteria for more than 6 months: Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT (oral glucose tolerance test);
  • HbA1c between 6.5-8.5 % (confirmed in the previous 3 months),
  • capable of using oral nutritional supplementation,
  • on stable and controlled anti-diabetic regime for at least 1 months,
  • use of metformin and/or sulphonylureas as oral anti-diabetic medication,
  • in need of nutritional support because of ≥5% involuntary weight loss in the last 3 months, ≥10% involuntary weight loss in the last 6 months, inadequate nutritional intake causing failure to meet nutritional requirements or at risk of developing malnutrition

Exclusion criteria

  • diabetes type 1,
  • participation in a clinical trial with an investigational product or regular use of disease-specific oral nutritional supplements within 4 weeks prior to study start
  • patients requiring a fibre free diet,
  • enteral tube feed or parenteral nutrition,
  • concomitant therapy with systemic glucocorticoids, insulins or anti-diabetic medication other than metformin and sulphonylureas,
  • known or suspected intolerance or allergy to any component of the investigational product(s),
  • any acute gastrointestinal disease within 2 weeks prior to study entry,
  • gastrectomy, gastroparesis or other gastric emptying abnormalities,
  • acute sever heart failure (NYHA class 4), liver insufficiency / failure (male: ALAT > 150 U/l; female: ALAT > 120 U/l) or renal failure requiring dialysis,
  • cancer cachexia,
  • galactosaemia, fructosaemia,
  • suspicion of drug abuse, abuse of/addiction to alcohol,
  • pregnant or breast feeding women, or fertile women refusing to use contraceptives,
  • patients with untreated major psychiatric disorder,
  • known HIV positive (safety reasons),
  • patient unable to co-operate adequately

Treatment and study plan

Oral nutritional supplement, food for special medical purposes

Dietary Supplement

2 servings of 200 ml per day, treatment period: 12 weeks

Primary outcomes

  1. postprandial blood glucose (iAUC) (0-240 min)

    Time frame: day 1

  2. postprandial blood glucose (iAUC) (0-240 min)

    Time frame: day 42

  3. postprandial blood glucose (iAUC) (0-240 min)

    Time frame: day 84

Secondary outcomes

  1. postprandial peak blood glucose (0-240 min)

    Time frame: day 1, day 42, day 84

  2. postprandial triglycerides (0-240 min)

    Time frame: day 1, day 42, day 84

  3. total cholesterol, HDL-cholesterol, LDL-cholesterol

    Time frame: day 1, day 42, day 84

  4. total protein, albumin, prealbumin

    Time frame: day 1, day 42, day 84

  5. HbA1c, HOMA-IR index

    Time frame: day 1, day 42, day 84

  6. c-peptide

    Time frame: day 1, day 84

  7. gastrointestinal tolerance

    Time frame: week 1, week 6, week 12

  8. palatability / taste test

    Time frame: week 1, week 6, week 12

    by means of a sensorial questionnaire the patients will evaluate the overall liking, appearance, smell, taste, mouth feel et cetera of the study nutrition.

  9. daily compliance

    Time frame: day 1-84

    in a daily compliance questionnaire the patients record the amount of oral nutritional supplements consumed.

Sponsors and collaborators

Lead sponsor

Fresenius Kabi

Industry

Registry information

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Nov 16, 2010
Registry last updated
Jul 2, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.